Senseonics (NYSE:SENS) Releases Earnings Results, Misses Expectations By $0.09 EPS

Senseonics (NYSE:SENS - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.09), RTT News reports. Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same quarter in the prior year, the firm earned ($0.07) EPS. Senseonics updated its FY 2025 guidance to EPS.

Senseonics Stock Up 5.3 %

Senseonics stock traded up $0.03 during mid-day trading on Friday, reaching $0.65. The company's stock had a trading volume of 11,502,141 shares, compared to its average volume of 14,658,552. The business's 50 day simple moving average is $0.86 and its 200 day simple moving average is $0.53. Senseonics has a 12 month low of $0.25 and a 12 month high of $1.40. The company has a market capitalization of $384.88 million, a price-to-earnings ratio of -4.97 and a beta of 1.17. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47.

Insider Activity

In other Senseonics news, CEO Timothy T. Goodnow acquired 315,000 shares of the business's stock in a transaction on Tuesday, December 10th. The stock was purchased at an average price of $0.31 per share, with a total value of $97,650.00. Following the acquisition, the chief executive officer now directly owns 11,310,355 shares of the company's stock, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the business's stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $0.38 per share, with a total value of $47,474.54. Following the acquisition, the chief financial officer now owns 2,478,844 shares in the company, valued at $941,960.72. This trade represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. Insiders own 3.60% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SENS shares. StockNews.com initiated coverage on shares of Senseonics in a research note on Thursday, December 26th. They set a "sell" rating on the stock. HC Wainwright restated a "buy" rating and issued a $2.00 price objective on shares of Senseonics in a report on Wednesday.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.